Key result
RBBB predicted mortality in de novo acute heart failure (HR 1.93; 95% CI 1.03-3.60; P=0.04), while IVCD predicted death in decompensated chronic heart failure (HR 1.79; 95% CI 1.28-2.52; P=0.001).
Why the study?
Do ventricular conduction abnormalities (LBBB, RBBB, IVCD) predict long-term mortality differently in de novo acute heart failure versus acutely decompensated chronic heart failure?
Cohort (n=982)
Yes
Do ventricular conduction abnormalities (LBBB, RBBB, IVCD) predict long-term mortality differently in de novo acute heart failure versus acutely decompensated chronic heart failure?
Effect estimate: adjusted HR 1.93 (95% CI 1.03-3.60)
Absolute Event Rate: 85.4% vs 57%
p-value: p=0.04
RBBB and IVCD are independent predictors of long-term mortality in de novo acute heart failure and acutely decompensated chronic heart failure, respectively, whereas LBBB does not independently predict mortality in hospitalized AHF patients.
RBBB and IVCD may differentially stratify mortality risk by acute HF type; leaves open targeted interventions pending prospective validation.
Aims Data on the prognostic role of left and right bundle branch blocks (LBBB and RBBB), and nonspecific intraventricular conduction delay (IVCD; QRS ≥ 110 ms, no BBB) in acute heart failure (AHF) are controversial. Our aim was to investigate electrocardiographic predictors of long-term survival in patients with de novo AHF and acutely decompensated chronic heart failure (ADCHF). Methods and Results We analysed the admission electrocardiogram of 982 patients from a multicenter European cohort of AHF with 3.9 years' mean follow-up. Half (51.5%, n = 506) of the patients had de novo AHF. LBBB, and IVCD were more common in ADCHF than in de novo AHF: 17.2% vs. 8.7% (P < 0.001) and 20.6% vs. 13.2% (P = 0.001), respectively, and RBBB was almost equally common (6.9% and 8.1%; P = 0.5), respectively. Mortality during the follow-up was higher in patients with RBBB (85.4%) and IVCD (73.7%) compared with patients with normal ventricular conduction (57.0%); P < 0.001 for both. The impact of RBBB on prognosis was prominent in de novo AHF (adjusted HR 1.93, 1.03–3.60; P = 0.04), and IVCD independently predicted death in ADCHF (adjusted HR 1.79, 1.28–2.52; P = 0.001). Both findings were pronounced in patients with reduced ejection fraction. LBBB showed no association with increased mortality in either of the subgroups. The main results were confirmed in a validation cohort of 1511 AHF patients with 5.9 years' mean follow-up. Conclusions Conduction abnormalities predict long-term survival differently in de novo AHF and ADCHF. RBBB predicts mortality in de novo AHF, and IVCD in ADCHF. LBBB has no additive predictive value in AHF requiring hospitalization.
No takes yet. Share an insight, caveat, or question.
Tolppanen et al. (2015) conducted a cohort in Acute heart failure (n=982). Ventricular conduction abnormalities (RBBB and IVCD) vs. Normal ventricular conduction was evaluated on Mortality (adjusted HR 1.93, 95% CI 1.03-3.60, p=0.04). RBBB predicted mortality in de novo acute heart failure (HR 1.93; 95% CI 1.03-3.60; P=0.04), while IVCD predicted death in decompensated chronic heart failure (HR 1.79; 95% CI 1.28-2.52; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: